Navigation Links
Study Models Impact Of Anthrax Vaccine

Rapidly distributing antibiotics to people exposed to anthrax spores during a bioterrorist attack, could by itself, prevent about 70 percent of anthrax infections from occurring, according to researchers from the Johns Hopkins Bloomberg School of Public Health. To increase the prevention rate to 90 percent, their study found that at least 63 percent of the population would need to be immunized with vaccine before an anthrax attack, which might not be practical. However, the study found that anthrax vaccination given even after an attack could be beneficial in reducing the length of time antibiotic treatment would be needed. These findings could be an important tool for policymakers who must develop effective strategies for containing an anthrax outbreak. The study is published in the December 16, 2004, edition of Nature.

The Hopkins researchers developed a probability model to predict how many cases of anthrax could be prevented under varying conditions. The study found that about 70 percent of anthrax cases could be prevented if antibiotics were distributed within 6 days after exposure and patients were to take them for 60 days. Prevention rates dropped below 50 percent if antibiotics were delayed more than 10 days. In 2001, some postal workers did not begin taking antibiotics until 9 days after exposure. The current licensed anthrax vaccine requires six doses over an 18-month period to provide immunity. The researchers looked at what impact a new and improved anthrax vaccine could have, and evaluated a range of vaccine characteristics, which could begin to provide immunity ranging between 7 and 28 days. When vaccine was distributed along with antibiotics after an attack, the researchers calculated that vaccine prevented few additional cases from occurring when compared to just rapid use of antibiotics. However, they found that if the vaccine is 95 percent effective, it could reduce the time that antibiotics would be needed up to 43 days. An 80 percent effec
'"/>

Source:Johns Hopkins Bloomberg School of Public Health


Page: 1 2

Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
3. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
4. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
5. Study Links Ebola Outbreaks To Animal Carcasses
6. Breakthrough Microarray-based Technology for the Study of Cancer
7. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
8. Study finds more than one-third of human genome regulated by RNA
9. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
10. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
11. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Study Models Impact Anthrax Vaccine

(Date:7/31/2015)... julio de 2015 BGI llevará a cabo la ... 22 al 25 de octubre de 2015, en ... celebra su décimo aniversario este año. Desde su inauguración ... las reuniones anuales más influyentes del mundo en los ... conferencias científicas más dinámicas, entusiastas y amenas. ...
(Date:7/31/2015)... -- Die 10. internationale Konferenz zu Genomik (ICG-10, ... findet vom 22. bis 25. Oktober 2015 in ... Die Konferenz feiert in diesem Jahr ... die ICG weltweit zu einem der einflussreichsten jährlichen ... der dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen Zusammentreffen. ...
(Date:7/27/2015)... JOSE, Calif. , July 27, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... ® touchscreen solution for its stylish smartwatch. ... for its proven reliability, low power and highly ... a wet finger. Huawei designers also required a ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3
... a tiny floating plant that,s been known to drive people ... that often becomes a hard-to-control weed in ponds and small ... and as a source to produce pharmaceuticals. Now, the genome ... miniscule plant,s potential as a biofuel source a big boost. ...
... a synthetic scaffolding material with gene delivery techniques, researchers ... to generate replacement cartilage where it,s needed in the ... requires applying copious amounts of growth factor proteins -- ... once the developing material is implanted within a body. ...
... 2014)The George Washington (GW) University School of Public Health ... on February 25 that will address the prevalence and ... event will feature a keynote talk by Mika Brzezinski, ... best-selling book "Obsessed: America,s Food Addiction---and My Own." ...
Cached Biology News:Pond-dwelling powerhouse's genome points to its biofuel potential 2Pond-dwelling powerhouse's genome points to its biofuel potential 3Pond-dwelling powerhouse's genome points to its biofuel potential 4Regenerating orthopedic tissues within the human body 2Regenerating orthopedic tissues within the human body 3Mika Brzezinski, co-host of MSNBC's 'Morning Joe,' to give keynote at GW event on eating disorders 2
(Date:8/26/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended June 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Oral Amp B program, rapidly advancing towards the ... Rae , President & CEO of iCo Therapeutics. "We ...
(Date:8/26/2015)... 26, 2015  Platform therapeutic company Symic Biomedical, ... a $1.5M Phase II SBIR grant from the ... its therapeutic agent to reduce arteriovenous fistula (AVF) ... stage renal disease (ESRD) patients undergoing hemodialysis. The ... Diabetes and Digestive and Kidney Diseases (NIDDK), will ...
(Date:8/26/2015)... , August 26, 2015 After ... against Europlasma NV relating to P2i United States ... resolved their dispute in the United States ... on the part of either party. As a result of ... District of California dismissed the case ...
(Date:8/25/2015)...   WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... company serving the pharmaceutical, biotechnology, and medical device industries, ... Exchange Stock Code: 0950), a research-based biopharmaceutical company headquartered ... years of operations in China , ... agreement whereby WuXi,s Laboratory Testing Division (LTD) will be ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3P2i Settles United States Litigation 2WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 2WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 3
... Ltd today announced that it has dosed the first ... its novel JAK2 inhibitor SB1518 in the U.S. and ... This multi-center, open-label, study is designed to ... patients with advanced lymphoid malignancies in five sites including ...
... 14, 2011 Reportlinker.com announces that a ... its catalogue: Neurology Devices ... Neurostimulation Devices, Interventional Neurology and Other ... Neurology Devices Market Outlook in China to ...
... industry & university cooperative research center program (I/UCRC) will ... testing of a wide range of metamaterials." Dr. ... Grove School of Engineering at The City College of ... for Metamaterials. Participating institutions are The ...
Cached Biology Technology:S*BIO Initiates Phase 2 Clinical Trial of its Novel JAK2 Inhibitor SB1518 in North America for Advanced Lymphoid Malignancies 2S*BIO Initiates Phase 2 Clinical Trial of its Novel JAK2 Inhibitor SB1518 in North America for Advanced Lymphoid Malignancies 3Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 2Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 3Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 4Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 5Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 6Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 7Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 8Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 9Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 10Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 11Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 12Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other 13Grove School professor leads new metamaterials center 2Grove School professor leads new metamaterials center 3Grove School professor leads new metamaterials center 4
... The Biomek FX provides ... analysis applications. With 96-, ... pipetting heads in either single ... Biomek FX offers maximum speed ...
... is the latest entry in the Biomek ... accuracy and increased robustness, it can meet the ... be configured with either one or two pipetting ... FX P sets the standard for flexible ...
... standard fixed-angle microcentrifuge rotor at RCF ... tube filters consist of a membrane-containing ... They filter by centrifugation for bacteria ... removal of cells from media and ...
These Costar 96-well, flat-bottom polystyrene EIA plates are used for EIAs, ELISAs, and other protein binding assays. Supplied as box of 100 (20 packages; 5 plates per package)....
Biology Products: